AstraZeneca stock slides as pivotal lung cancer readout on Daiichi-partnered ADC spooks investors

AstraZeneca and Daiichi Sankyo’s attempt to repeat the success of Enhertu has delivered its first phase 3 data. The antibody-drug conjugate (ADC) improved progression-free survival (PFS) in lung cancer patients but, with the partners yet to share numbers and “some” patients suffering fatal adverse events, shares in AstraZeneca fell almost 6% in early trading in London.